Regentis Biomaterials Balance Sheet Analysis

Assets, liabilities, and stockholders equity in millions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for Regentis Biomaterials Ltd. (RGNT) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Current Assets
Cash and Cash Equivalents0.230.351.242.741.38
Cash & Short-Term Investments0.230.351.242.741.38
Accounts Receivable0.070.010.030.050.01
Inventory0.000.000.000.000.00
Other Current Assets0.180.010.450.330.00
Total Current Assets0.480.361.723.121.39
Non-Current Assets
Property, Plant & Equipment (Net)0.000.000.000.000.00
Other Non-Current Assets0.000.000.000.000.00
Total Non-Current Assets0.000.000.000.000.00
Total Assets0.480.361.723.121.39
Current Liabilities
Accounts Payable0.250.350.210.310.33
Short-Term Debt4.370.216.470.000.00
Current Portion of Long-Term Debt4.370.006.470.000.00
Accrued Liabilities1.130.520.420.200.00
Deferred Revenue0.002.051.982.211.21
Other Current Liabilities0.160.000.000.000.00
Total Current Liabilities6.493.142.612.721.54
Non-Current Liabilities
Long-Term Debt0.007.416.476.080.47
Other Non-Current Liabilities0.000.620.690.790.70
Total Non-Current Liabilities35.1043.1341.1740.870.00
Total Liabilities6.4911.1743.789.582.71
Stockholders' Equity
Retained Earnings-42.15-46.95-42.82-41.23-36.09
Additional Paid-in Capital1.041.040.750.750.00
Shares Outstanding4.934.934.934.930.00
Total Stockholders' Equity-6.01-10.81-42.06-6.47-1.33
Total Liabilities & Equity0.480.361.723.120.00